The structural heart market size has grown strongly in recent years. It will grow from $15.89 billion in 2025 to $17.31 billion in 2026 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to increasing prevalence of valvular heart diseases, aging global population, expansion of catheterization laboratories, adoption of transcatheter heart technologies, rising awareness of minimally invasive cardiac care.
The structural heart market size is expected to see strong growth in the next few years. It will grow to $24.6 billion in 2030 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to growing demand for transcatheter therapies, increasing investments in structural heart programs, expansion of cardiac centers of excellence, advancements in device miniaturization, rising focus on reducing open-heart surgery rates. Major trends in the forecast period include increasing adoption of transcatheter valve procedures, rising use of minimally invasive structural heart interventions, growing integration of advanced cardiac imaging, expansion of catheter-based repair technologies, enhanced focus on patient-specific treatment planning.
The rising prevalence of cardiovascular disorders is expected to drive growth in the structural heart market in the coming years. Cardiovascular disorders are conditions affecting the heart and blood vessels, including coronary artery disease, heart failure, and stroke. This increase is primarily driven by aging populations, lifestyle and dietary changes, and rising rates of obesity and diabetes. Structural heart devices and services provide diagnosis and treatment for anomalies affecting the heart’s valves, chambers, and surrounding tissues through minimally invasive procedures rather than open-heart surgery, enabling efficient treatment with lower complication risks. For example, in September 2025, the British Heart Foundation, a UK-based charity, reported that over 7.6 million people in the UK - more than 4 million men and over 3.6 million women - were living with cardiovascular disease, with projections suggesting the number could increase by about 1 million by 2030 and roughly 2 million by 2040 due to an aging population and improved survival rates. Thus, the rising prevalence of cardiovascular disorders is propelling the structural heart market.
Key players in the structural heart market are innovating advanced products, including transcatheter edge-to-edge repair (TEER) systems, to improve minimally invasive treatment options for heart valve diseases. TEER systems are minimally invasive medical devices designed to address heart valve conditions, particularly mitral valve regurgitation. For example, in April 2024, Abbott Laboratories, a US-based medical device firm, gained approval from the Food and Drug Administration (FDA), a US federal agency responsible for safeguarding public health, for its device called TriClip. TriClip is an innovative TEER system that is delivered through a vein in the leg, allowing for valve repair without the need for open-heart surgery, making it suitable for patients who might be at greater risk due to age or pre-existing health conditions. The device operates by using clips to grasp and bring together the leaflets of the tricuspid valve, thereby decreasing regurgitation and enhancing blood flow.
In July 2024, Edwards Lifesciences, a US-based provider of structural heart disease therapies and critical care monitoring technologies, acquired JenaValve Technology and Endotronix for approximately USD 1.2 billion. Through this acquisition, Edwards aims to broaden its structural heart portfolio by entering new therapeutic areas, strengthening its innovation pipeline, and addressing unmet needs in aortic regurgitation and heart failure care. JenaValve Technology, based in Germany, develops transcatheter aortic valve replacement solutions for aortic regurgitation, while Endotronix, a US-based company, provides implantable hemodynamic monitoring systems and digital heart failure management platforms.
Major companies operating in the structural heart market are Abbott Laboratories, Medtronic plc, Boston Scientific Corporation, Edwards Lifesciences Corporation, Lepu Medical Technology Co. Ltd., LivaNova PLC, Venus Medtech (Hangzhou) Inc., CryoLife Inc., Endologix Inc., Braile Biomédica, JenaValve Technology Inc., Corvia Medical Inc., On-X Life Technologies Inc., Symetis SA, Micro Interventional Devices Inc., CardioKinetix Inc., Tendyne Holdings Inc., Neovasc Inc., NVT AG, Biomerics LLC, Shockwave Medical Inc., HLT Medical, Q'Apel Medical Inc., Z-Medical GmbH + Co. KG.
North America was the largest region in the structural heart market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the structural heart market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the structural heart market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the structural heart market by increasing costs of imported catheters, imaging systems, delivery devices, and implantable components used in valve repair and closure procedures. Healthcare providers in North America and Europe are most affected due to reliance on advanced imported devices, while Asia-Pacific faces higher costs for exported cardiac technologies. These tariffs are elevating procedural expenses and slowing adoption in cost-sensitive regions. At the same time, they are encouraging local device manufacturing, regional R&D investments, and supply chain diversification.
The structural heart market research report is one of a series of new reports that provides structural heart market statistics, including structural heart industry global market size, regional shares, competitors with a structural heart market share, detailed structural heart market segments, market trends and opportunities, and any further data you may need to thrive in the structural heart industry. This structural heart market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Structural heart is a subspecialty within cardiology that concentrates on diagnosing and treating structural abnormalities or diseases of the heart, particularly those impacting the valves, chambers, and surrounding structures. This field typically involves minimally invasive procedures conducted in a catheterization laboratory as opposed to traditional open-heart surgery.
The primary categories of structural heart products encompass occluders, annuloplasty rings, heart valve balloons, and other related devices. Occluder systems are specifically designed to provide a conduit for delivering devices into the heart's chambers, coronary arteries, and peripheral vasculature. These devices are utilized in patients with specific types of atrial septal defects featuring right atrial or ventricle enlargement, preventing paradoxical embolism. The diverse procedures employing structural heart products include heart valve stenosis, heart valve regurgitation, and left atrial appendage closure. These procedures cater to various end-users such as hospitals, ambulatory surgical centers, and cardiac centers.
The structural heart market consists of revenues earned by entities by providing services such as patient evaluation, diagnosis, treatment planning, surgical or interventional procedures, and follow-up care. The market value includes the value of related goods sold by the service provider or included within the service offering. The structural heart market also includes sales of transcatheter heart valves, closure devices, and implantable devices that are used during procedures. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The structural heart market size is expected to see strong growth in the next few years. It will grow to $24.6 billion in 2030 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to growing demand for transcatheter therapies, increasing investments in structural heart programs, expansion of cardiac centers of excellence, advancements in device miniaturization, rising focus on reducing open-heart surgery rates. Major trends in the forecast period include increasing adoption of transcatheter valve procedures, rising use of minimally invasive structural heart interventions, growing integration of advanced cardiac imaging, expansion of catheter-based repair technologies, enhanced focus on patient-specific treatment planning.
The rising prevalence of cardiovascular disorders is expected to drive growth in the structural heart market in the coming years. Cardiovascular disorders are conditions affecting the heart and blood vessels, including coronary artery disease, heart failure, and stroke. This increase is primarily driven by aging populations, lifestyle and dietary changes, and rising rates of obesity and diabetes. Structural heart devices and services provide diagnosis and treatment for anomalies affecting the heart’s valves, chambers, and surrounding tissues through minimally invasive procedures rather than open-heart surgery, enabling efficient treatment with lower complication risks. For example, in September 2025, the British Heart Foundation, a UK-based charity, reported that over 7.6 million people in the UK - more than 4 million men and over 3.6 million women - were living with cardiovascular disease, with projections suggesting the number could increase by about 1 million by 2030 and roughly 2 million by 2040 due to an aging population and improved survival rates. Thus, the rising prevalence of cardiovascular disorders is propelling the structural heart market.
Key players in the structural heart market are innovating advanced products, including transcatheter edge-to-edge repair (TEER) systems, to improve minimally invasive treatment options for heart valve diseases. TEER systems are minimally invasive medical devices designed to address heart valve conditions, particularly mitral valve regurgitation. For example, in April 2024, Abbott Laboratories, a US-based medical device firm, gained approval from the Food and Drug Administration (FDA), a US federal agency responsible for safeguarding public health, for its device called TriClip. TriClip is an innovative TEER system that is delivered through a vein in the leg, allowing for valve repair without the need for open-heart surgery, making it suitable for patients who might be at greater risk due to age or pre-existing health conditions. The device operates by using clips to grasp and bring together the leaflets of the tricuspid valve, thereby decreasing regurgitation and enhancing blood flow.
In July 2024, Edwards Lifesciences, a US-based provider of structural heart disease therapies and critical care monitoring technologies, acquired JenaValve Technology and Endotronix for approximately USD 1.2 billion. Through this acquisition, Edwards aims to broaden its structural heart portfolio by entering new therapeutic areas, strengthening its innovation pipeline, and addressing unmet needs in aortic regurgitation and heart failure care. JenaValve Technology, based in Germany, develops transcatheter aortic valve replacement solutions for aortic regurgitation, while Endotronix, a US-based company, provides implantable hemodynamic monitoring systems and digital heart failure management platforms.
Major companies operating in the structural heart market are Abbott Laboratories, Medtronic plc, Boston Scientific Corporation, Edwards Lifesciences Corporation, Lepu Medical Technology Co. Ltd., LivaNova PLC, Venus Medtech (Hangzhou) Inc., CryoLife Inc., Endologix Inc., Braile Biomédica, JenaValve Technology Inc., Corvia Medical Inc., On-X Life Technologies Inc., Symetis SA, Micro Interventional Devices Inc., CardioKinetix Inc., Tendyne Holdings Inc., Neovasc Inc., NVT AG, Biomerics LLC, Shockwave Medical Inc., HLT Medical, Q'Apel Medical Inc., Z-Medical GmbH + Co. KG.
North America was the largest region in the structural heart market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the structural heart market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the structural heart market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the structural heart market by increasing costs of imported catheters, imaging systems, delivery devices, and implantable components used in valve repair and closure procedures. Healthcare providers in North America and Europe are most affected due to reliance on advanced imported devices, while Asia-Pacific faces higher costs for exported cardiac technologies. These tariffs are elevating procedural expenses and slowing adoption in cost-sensitive regions. At the same time, they are encouraging local device manufacturing, regional R&D investments, and supply chain diversification.
The structural heart market research report is one of a series of new reports that provides structural heart market statistics, including structural heart industry global market size, regional shares, competitors with a structural heart market share, detailed structural heart market segments, market trends and opportunities, and any further data you may need to thrive in the structural heart industry. This structural heart market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Structural heart is a subspecialty within cardiology that concentrates on diagnosing and treating structural abnormalities or diseases of the heart, particularly those impacting the valves, chambers, and surrounding structures. This field typically involves minimally invasive procedures conducted in a catheterization laboratory as opposed to traditional open-heart surgery.
The primary categories of structural heart products encompass occluders, annuloplasty rings, heart valve balloons, and other related devices. Occluder systems are specifically designed to provide a conduit for delivering devices into the heart's chambers, coronary arteries, and peripheral vasculature. These devices are utilized in patients with specific types of atrial septal defects featuring right atrial or ventricle enlargement, preventing paradoxical embolism. The diverse procedures employing structural heart products include heart valve stenosis, heart valve regurgitation, and left atrial appendage closure. These procedures cater to various end-users such as hospitals, ambulatory surgical centers, and cardiac centers.
The structural heart market consists of revenues earned by entities by providing services such as patient evaluation, diagnosis, treatment planning, surgical or interventional procedures, and follow-up care. The market value includes the value of related goods sold by the service provider or included within the service offering. The structural heart market also includes sales of transcatheter heart valves, closure devices, and implantable devices that are used during procedures. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Structural Heart Market Characteristics
3. Structural Heart Market Supply Chain Analysis
4. Global Structural Heart Market Trends and Strategies
5. Structural Heart Market Analysis of End Use Industries
7. Global Structural Heart Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Structural Heart Total Addressable Market (TAM) Analysis for the Market
9. Structural Heart Market Segmentation
10. Structural Heart Market Regional and Country Analysis
11. Asia-Pacific Structural Heart Market
12. China Structural Heart Market
13. India Structural Heart Market
14. Japan Structural Heart Market
15. Australia Structural Heart Market
16. Indonesia Structural Heart Market
17. South Korea Structural Heart Market
18. Taiwan Structural Heart Market
19. South East Asia Structural Heart Market
20. Western Europe Structural Heart Market
21. UK Structural Heart Market
22. Germany Structural Heart Market
23. France Structural Heart Market
24. Italy Structural Heart Market
25. Spain Structural Heart Market
26. Eastern Europe Structural Heart Market
27. Russia Structural Heart Market
28. North America Structural Heart Market
29. USA Structural Heart Market
30. Canada Structural Heart Market
31. South America Structural Heart Market
32. Brazil Structural Heart Market
33. Middle East Structural Heart Market
34. Africa Structural Heart Market
36. Structural Heart Market Competitive Landscape and Company Profiles
37. Structural Heart Market Other Major and Innovative Companies
40. Structural Heart Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Structural Heart Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses structural heart market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for structural heart? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The structural heart market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product: Occluders; Annuloplasty Rings; Heart Valve Balloons; Other Products2) By Procedure: Heart Valve Stenosis; Heart Valve Regurgitation; Left Atrial Appendage Closure
3) By End Users: Hospitals; Cardiac Centers
Subsegments:
1) By Occluders: Atrial Septal Defect (ASD) Occluders; Patent Foramen Ovale (PFO) Occluders; Ventricular Septal Defect (VSD) Occluders2) By Annuloplasty Rings: Rigid Annuloplasty Rings; Flexible Annuloplasty Rings; Adjustable Annuloplasty Rings
3) By Heart Valve Balloons: Balloon Expandable Heart Valve Systems; Valvuloplasty Balloons
4) By Other Products: Transcatheter Heart Valves; Structural Heart Imaging Devices; Delivery Systems For Structural Heart Procedures
Companies Mentioned: Abbott Laboratories; Medtronic plc; Boston Scientific Corporation; Edwards Lifesciences Corporation; Lepu Medical Technology Co. Ltd.; LivaNova PLC; Venus Medtech (Hangzhou) Inc.; CryoLife Inc.; Endologix Inc.; Braile Biomédica; JenaValve Technology Inc.; Corvia Medical Inc.; On-X Life Technologies Inc.; Symetis SA; Micro Interventional Devices Inc.; CardioKinetix Inc.; Tendyne Holdings Inc.; Neovasc Inc.; NVT AG; Biomerics LLC; Shockwave Medical Inc.; HLT Medical; Q'Apel Medical Inc.; Z-Medical GmbH + Co. KG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Structural Heart market report include:- Abbott Laboratories
- Medtronic plc
- Boston Scientific Corporation
- Edwards Lifesciences Corporation
- Lepu Medical Technology Co. Ltd.
- LivaNova PLC
- Venus Medtech (Hangzhou) Inc.
- CryoLife Inc.
- Endologix Inc.
- Braile Biomédica
- JenaValve Technology Inc.
- Corvia Medical Inc.
- On-X Life Technologies Inc.
- Symetis SA
- Micro Interventional Devices Inc.
- CardioKinetix Inc.
- Tendyne Holdings Inc.
- Neovasc Inc.
- NVT AG
- Biomerics LLC
- Shockwave Medical Inc.
- HLT Medical
- Q'Apel Medical Inc.
- Z-Medical GmbH + Co. KG
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 17.31 Billion |
| Forecasted Market Value ( USD | $ 24.6 Billion |
| Compound Annual Growth Rate | 9.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 25 |
